Literature DB >> 31610965

Is less really more? Reexamining video-assisted thoracoscopic versus open lobectomy in the setting of an enhanced recovery protocol.

Elizabeth D Krebs1, J Hunter Mehaffey1, Bethany M Sarosiek1, Randal S Blank2, Christine L Lau1, Linda W Martin3.   

Abstract

OBJECTIVES: Video-assisted thoracoscopic surgery lobectomy has been associated with improved pain, length of stay, and outcomes compared with open lobectomy. However, enhanced recovery protocols improve outcomes after both procedures. We aimed to compare video-assisted thoracoscopic surgery and open lobectomy in the setting of a comprehensive enhanced recovery protocol.
METHODS: All patients undergoing lobectomy for lung cancer at a single institution since the adoption of an enhanced recovery protocol (May 2016 to December 2018) were stratified by video-assisted thoracoscopic surgery versus open status and compared. Demographics and outcomes, including length of stay, daily pain scores, and short-term operative complications, were compared using standard univariate statistics and multivariable models.
RESULTS: A total of 130 patients underwent lobectomy, including 71 (54.6%) undergoing video-assisted thoracoscopic surgery and 59 (45.4%) undergoing open surgery. Video-assisted thoracoscopic surgery versus open cases exhibited similar length of stay (median 4 days for both, P = .07), opioid requirement (33.2 vs 30.8 mg morphine equivalents, P = .86), and pain scores at 0, 1, 2, and 3 days after surgery (4.3 vs 2.8, P = .12; 4.4 vs 3.7, P = .27; 3.9 vs 3.5, P = .83; and 3.4 vs 3.5, P = .98, respectively). Patients undergoing video-assisted thoracoscopic surgery lobectomy exhibited lower rates of readmission (1.4% vs 17.0%, P < .01), postoperative transfusion requirement (0% vs 10.2%, P < .01), and pneumonia (1.4% vs 10.2%, P = .05). After risk adjustment, an open procedure (vs video-assisted thoracoscopic surgery status) did not significantly affect the length of stay (effect 0.18; P = .10) or overall complication rate (odds ratio, 1.9; P = .12).
CONCLUSIONS: In the setting of a comprehensive enhanced recovery protocol, patients undergoing video-assisted thoracoscopic surgery versus open lobectomy exhibited similar short-term outcomes. Surgical incision may have less impact on outcomes in the setting of a comprehensive thoracic enhanced recovery protocol.
Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  enhanced recovery; lobectomy; lung cancer; video-assisted thoracoscopic surgery

Year:  2019        PMID: 31610965     DOI: 10.1016/j.jtcvs.2019.08.036

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Implementation of an enhanced recovery after thoracic surgery care pathway for thoracotomy patients-achieving better pain control with less (schedule II) opioid utilization.

Authors:  Karishma Kodia; Joy A Stephens-McDonnough; Ahmed Alnajar; Nestor R Villamizar; Dao M Nguyen
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

2.  Comparative Effectiveness of Surgical Approaches for Lung Cancer.

Authors:  Adwaiy Manerikar; Melissa Querrey; Emily Cerier; Samuel Kim; David D Odell; Lorenzo L Pesce; Ankit Bharat
Journal:  J Surg Res       Date:  2020-12-09       Impact factor: 2.417

3.  Using a risk model for probability of cancer in pulmonary nodules.

Authors:  Si-Qi Liu; Xiao-Bin Ma; Wan-Mei Song; Yi-Fan Li; Ning Li; Li-Na Wang; Jin-Yue Liu; Ning-Ning Tao; Shi-Jin Li; Ting-Ting Xu; Qian-Yun Zhang; Qi-Qi An; Bin Liang; Huai-Chen Li
Journal:  Thorac Cancer       Date:  2021-05-11       Impact factor: 3.500

4.  Enhanced Recovery After Surgery Protocol Minimizes Intensive Care Unit Utilization and Improves Outcomes Following Pulmonary Resection.

Authors:  Terrance Peng; Kimberly A Shemanski; Li Ding; Elizabeth A David; Anthony W Kim; Michael Kim; Dustin K Lieu; Sean C Wightman; Jasmine Zhao; Scott M Atay
Journal:  World J Surg       Date:  2021-08-04       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.